MFN Pricing Could Upend Drugmakers' Cross-Border Deals
A new program rolled out by the Trump administration that aims to decrease prescription drug prices in the U.S. has been causing consternation among drug companies, which fear the resulting pricing...To view the full article, register now.
Already a subscriber? Click here to view full article